TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation for the treatment of neurodegenerative and inflammatory diseases, has announced the closing of its $31 million (£25 million) seed funding round. The company is co-founded by Prof Will McEwan (UK DRI at Cambridge) with Dr Leo James (MRC Laboratory of Molecular Biology).
TRIMTECH is leveraging the innate properties of a protein called TRIM21, co-discovered by Prof McEwan during his postdoctoral studies, to selectively and potently degrade protein aggregates associated with a range of diseases. Based on research conducted at the UK DRI at Cambridge and the MRC LMB, this approach harnesses TRIM21’s unique properties to develop new small molecule drugs for people affected by neurodegenerative conditions.
Fifteen years since our discovery of TRIM21 as the cytosolic antibody receptor, TRIMTECH will take forward our mechanism-based approach for potently and selectively removing assembled protein species. The company has assembled a world-class cluster of scientists and I am incredibly excited to see what the team can deliver.
Group Leader
Nicola Thompson, CEO, TRIMTECH, said:
“This oversubscribed financing round and the outstanding quality of our investor syndicate is a great endorsement of TRIMTECH’s unique approach to targeting the selective removal of aggregated proteins that underpin so many CNS diseases, and recognizes our impressive scientific foundations and world class team. We extend our thanks to all of our supporters and look forward to working with the new Board members, as we now push forward with progressing the pipeline.”
Source: TRIMTECH
